Balaji Amines Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹468 Cr +37.2% YoYSee revenue, profit and what management said. You are viewing Q3 FY25.
BA

Balaji Amines Ltd

Q3 FY25Chemicals & Petrochemicals

Balaji Amines Q3 FY25: Revenue ₹321 Cr, PAT ₹31 Cr

Q3 FY25 investor presentation: what the company reported on revenue, margins and capex.

Revenue
₹313Cr
−18.3% YoY
−9.8% QoQ
Net profit
₹31Cr
−44.6% YoY
−24.4% QoQ
Margin
15%
−4 pp YoY
−2 pp QoQ

Based on Balaji Amines Ltd's Q3 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹2,226
Market cap₹7.0K Cr
P/E34.5

The short version

Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Q3FY25 Consolidated EBITDA: ₹54 crore, down 35% YoY from ₹83 crore in Q3FY24 (Page 6) - Q3FY25 Consolidated EBITDA margin: 17%, down from 21% in Q3FY24 (Pages 6 and 7) - Q3FY25 Consolidated Profit

From Balaji Amines Ltd's Q3 FY25 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7).
  • Total volumes in Q3FY25 stood at 24,097 MT vs.
  • Segment volumes for Q3FY25: Amines 7,515 MT, Amines Derivatives 8,809 MT, Specialty Chemicals 7,773 MT (Page 7).
  • Standalone revenue for Q3FY25 was ₹305 crore, down 3% YoY from ₹315 crore (Page 6).

2 more points from Balaji Amines Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Balaji Amines Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Unit 4 Greenfield Phase 2 & 3 Capex: Ongoing, to be completed by FY 2026, includes n-Butylamine plant (15,000 TPA), Dimethyl Ether (DME) plant (100,000 TPA) commissioning expected by June 2025, and increased capacity utilization of Phase 1 Ethylamines plant.
  • N-Butylamine plant: Market demand ~8,000 tons, executed on schedule.
  • Methylamines capacity expansion: From 48,000 TPA to 88,000 TPA, commissioned Nov 2024.
  • NBPT plant (N-(N-Butyl) Thiophosphoric Triamide): 2,500 TPA, planned for next financial year.
  • ACN plant at Unit-III MIDC Chincholi: 60 MT/Day capacity, under detailed engineering, expected commissioning FY 2025-26.
  • Subsidiary Balaji Speciality Chemicals: Rs. 750 crore phased expansion with Mega Project status covering multiple chemicals (e.g., Hydrogen Cyanide, Sodium Cyanide, EDTA).
  • Solar Power Plant: 20 MW capacity near MIDC Chincholi; Phase 1 (8 MW DC) expected commissioning FY 2024-25.

2 more points from Balaji Amines Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Balaji Amines Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Balaji Amines Ltd said on order book & pipeline — free account, 30 seconds.

Balaji Amines Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Balaji Amines Ltd Q3 FY25 results — key figures

Balaji Amines Ltd Q3 FY25 reported results vs Q3 FY24, ₹ crore
₹ CrQ3 FY25Q3 FY24YoYQ2 FY25QoQ
Revenue313383-18.3%347-9.8%
Operating profit (EBITDA)4674-37.8%61-24.6%
Operating margin15%19%-4 pp17%-2 pp
Profit before tax4170-41.4%57-28.1%
Net profit (PAT)3156-44.6%41-24.4%
EPS (₹)10.2415.24-32.8%12.65-19.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹468 Cr, net profit ₹67 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Himadri Special (Q3 FY25)

    1,131.81 Crs, up 7.53% YoY (from Rs. Key concall takeaways from Himadri Speciality Chemical Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

  • Gujarat Alkalies (Q3 FY25)

    3,702.77 Crores (up from Rs. Key concall takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

  • Vidhi Specialty (Q3 FY25)

    Year-on-Year (Y-o-Y) Growth:** 56.5% increase . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY25 earnings call — and how it ranks…

  • Chemcon Speciality Chemicals (Q3 FY25)

    54.4 Cr, up 3% YoY from Rs. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Balaji Amines Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Balaji Amines Ltd Q3 FY25 results?

Q3FY25 consolidated revenue from operations was ₹321 crore, down 18% YoY from ₹392 crore in Q3FY24 (Page 7). Q3FY25 Consolidated EBITDA: ₹54 crore, down 35% YoY from ₹83 crore in Q3FY24 (Page 6) - Q3FY25 Consolidated EBITDA margin: 17%, down from 21% in Q3FY24 (Pages 6 and 7) - Q3FY25 Consolidated Profit

What is Balaji Amines Ltd share price analysis?

Balaji Amines Ltd currently shows a neutral. The stock trades at a P/E of 34.5 with a market cap of ₹7,036 Cr. Investors should review the full earnings analysis for detailed insights.

Is Balaji Amines Ltd planning capital expenditure?

Unit 4 Greenfield Phase 2 & 3 Capex: Ongoing, to be completed by FY 2026, includes n-Butylamine plant (15,000 TPA), Dimethyl Ether (DME) plant (100,000 TPA) commissioning expected by June 2025, and increased capacity utilization of Phase 1 Ethylamines plant.

Keep Balaji Amines Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.